{
    "symbol": "CAPR",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-10 20:21:07",
    "content": " These statements may include statements regarding, among other things, the efficacy, safety, and intended utilization of our product candidates, our future R&D plans, including our anticipated conduct and timing of preclinical and clinical studies; our plans to present or report additional data; our plans regarding regulatory filings, potential regulatory developments involving our product candidates, potential milestone payments; and our possible uses of existing cash and investment resources. We believe this data must be shown to FDA, both because of its statistical power and clinical benefit, but also because time is muscle, based on this dataset, every year that patients are off CAP-1002, they lose function that cannot be recovered, based on our regulatory designations of RMAT, or Regenerative Medicine Advanced Therapy and orphan disease designation, and also the importance of this data to people with DMD. This is a rest of your life kind of therapeutic, the way one visioning right now which just to highlight half of the patients with DMD right now are non-ambulant, that's 10,000 patients that make 10,000 boys, approximately eligible for four times a year dosing started between 10 and 15 years of age and going until 25 or 30 years of age, which is now when they typically pass away could be longer if everything works well."
}